Cargando…

Idiopathic Plasmacytic Lymphadenopathy Forms an Independent Subtype of Idiopathic Multicentric Castleman Disease

Idiopathic multicentric Castleman disease (iMCD) is a type of Castleman disease that is not related to KSHV/HHV8 infection. Currently, iMCD is classified into iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly) and iMCD-NOS (not otherwise specified). The former has b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishikori, Asami, Nishimura, Midori Filiz, Nishimura, Yoshito, Otsuka, Fumio, Maehama, Kanna, Ohsawa, Kumiko, Momose, Shuji, Nakamura, Naoya, Sato, Yasuharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9499480/ https://www.ncbi.nlm.nih.gov/pubmed/36142213 http://dx.doi.org/10.3390/ijms231810301

Ejemplares similares

Idiopathic multicentric Castleman disease with positive antiphospholipid antibody: atypical and undiagnosed autoimmune disease?
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Clinical and Pathological Characteristics of Hyaline-Vascular Type Unicentric Castleman Disease: A 20-Year Retrospective Analysis
por: Nishimura, Midori Filiz, et al.
Publicado: (2021)

Castleman disease, TAFRO syndrome, idiopathic plasmacytic lymphadenopathy, and autoimmune disease
por: Nakamura, Naoya
Publicado: (2022)

Historical and pathological overview of Castleman disease
por: Nishimura, Midori Filiz, et al.
Publicado: (2022)

Investigation of IgG4‐positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4‐related disease
por: Nishikori, Asami, et al.
Publicado: (2021)

Global public awareness of Castleman disease and TAFRO syndrome between 2015 and 2021: A Google Trends analysis
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease
por: Nishimura, Midori Filiz, et al.
Publicado: (2020)

Primary Gastrointestinal T-Cell Lymphoma and Indolent Lymphoproliferative Disorders: Practical Diagnostic and Treatment Approaches
por: Nishimura, Midori Filiz, et al.
Publicado: (2021)

Idiopathic plasmacytic lymphadenopathy: A conceptual history along with a translation of the original Japanese article published in 1980
por: Takeuchi, Kengo
Publicado: (2022)

Localized Plaques on the Scalp as Initial Presentation of Multicentric Plasmacytic Castleman Disease
por: Zhang, Heng, et al.
Publicado: (2022)

Upregulated Expression of Activation-Induced Cytidine Deaminase in Ocular Adnexal Marginal Zone Lymphoma with IgG4-Positive Cells
por: Nishikori, Asami, et al.
Publicado: (2021)

Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
por: Ha, Gavin, et al.
Publicado: (2023)

PD‐L1 expression is associated with the spontaneous regression of patients with methotrexate‐associated lymphoproliferative disorders
por: Gion, Yuka, et al.
Publicado: (2021)

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease
por: van Rhee, Frits, et al.
Publicado: (2022)

International definition of iMCD-TAFRO: future perspectives
por: Nishimura, Yoshito, et al.
Publicado: (2022)

Candidate biomarkers for idiopathic multicentric Castleman disease
por: Sumiyoshi, Remi, et al.
Publicado: (2022)

Alveolar Hemorrhage in Idiopathic Multicentric Castleman’s Disease
por: Huang, Lingtong, et al.
Publicado: (2023)

Multicentric Castleman's Disease, Associated with Idiopathic Thrombocytopenic Purpura
por: Sood, Ruchi, et al.
Publicado: (2013)

Idiopathic Multicentric Hyaline Vascular-Type Castleman Disease
por: Moutinho, Adelaide, et al.
Publicado: (2021)

Hemosiderin deposition in lymph nodes of patients with plasma cell-type Castleman disease
por: Han, Yanyan, et al.
Publicado: (2020)

P1140: TIME TO TUMOR, SYMPTOMATIC AND LABORATORY RESPONSES FOLLOWING SILTUXIMAB TREATMENT IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE
por: van Rhee, F., et al.
Publicado: (2022)

Idiopathic Multicentric Castleman Disease with Cutaneous Manifestation: Case Report
por: Kosmidis, Christoforos S., et al.
Publicado: (2022)

The lymph node transcriptome of unicentric and idiopathic multicentric Castleman disease
por: Horna, Pedro, et al.
Publicado: (2022)

Cytopathological Findings of Secretory Carcinoma of the Salivary Gland and the Diagnostic Utility of Giemsa Staining
por: Egusa, Yuria, et al.
Publicado: (2021)

Epstein–Barr Virus-Positive Mucocutaneous Ulcer: A Unique and Curious Disease Entity
por: Ikeda, Tomoka, et al.
Publicado: (2021)

A Rare Variant of Idiopathic Multicentric Castleman Disease: TAFRO Syndrome
por: Ük, Ece, et al.
Publicado: (2022)

CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
por: Pierson, Sheila K., et al.
Publicado: (2022)

Radiological and Pathological Features of Cyst Formation in Idiopathic Multicentric Castleman Disease
por: Otoshi, Ryota, et al.
Publicado: (2023)

Evaluation of Selected Cytokine Gene Expression in Colonic Mucosa from Dogs with Idiopathic Lymphocytic-plasmacytic Colitis
por: TAMURA, Yu, et al.
Publicado: (2014)

Virome capture sequencing does not identify active viral infection in unicentric and idiopathic multicentric Castleman disease
por: Nabel, Christopher S., et al.
Publicado: (2019)

An unexpected case of Castleman disease in porta hepatis lymphadenopathy
por: Li, Crystal, et al.
Publicado: (2023)

Idiopathic multicentric Castleman disease preceded by cutaneous plasmacytosis successfully treated by tocilizumab
por: Aita, Tetsuro, et al.
Publicado: (2020)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Cutaneous plasmacytosis: A rare initial presentation of idiopathic multicentric Castleman's disease
por: Yamamoto, Yu, et al.
Publicado: (2021)

Idiopathic Multicentric Castleman Disease Presenting With Hypertensive Choroidopathy: A Case Report
por: Mimoto, Tamami, et al.
Publicado: (2023)

Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes
por: Pierson, Sheila K., et al.
Publicado: (2023)

Diagnostic Utility of SOX4 Expression in Adult T-Cell Leukemia/Lymphoma
por: Nasu, Atsuko, et al.
Publicado: (2021)

Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis
por: Wallis, Tim JM, et al.
Publicado: (2022)

The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman’s disease
por: Min, Gi-June, et al.
Publicado: (2021)

Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report
por: Lang, Evan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_elh9u2536i17e8islrqrb8djua